Pfizer Inc. (NYSE:PFE) Shares Sold by Atlas Private Wealth Advisors

Atlas Private Wealth Advisors lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 42.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,452 shares of the biopharmaceutical company's stock after selling 24,881 shares during the period. Atlas Private Wealth Advisors' holdings in Pfizer were worth $848,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in PFE. Mcdonald Partners LLC grew its stake in Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after buying an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $264,000. ING Groep NV increased its holdings in Pfizer by 48.6% in the fourth quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock valued at $26,881,000 after buying an additional 331,403 shares in the last quarter. Strategic Financial Concepts LLC acquired a new position in Pfizer in the 4th quarter worth about $2,281,000. Finally, Sage Mountain Advisors LLC raised its stake in shares of Pfizer by 7.3% during the 4th quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company's stock worth $546,000 after buying an additional 1,404 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Trading Down 0.5%

Shares of NYSE PFE traded down $0.13 during trading on Wednesday, reaching $23.88. The stock had a trading volume of 36,979,882 shares, compared to its average volume of 41,200,926. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market cap of $135.74 billion, a P/E ratio of 17.30, a PEG ratio of 0.89 and a beta of 0.57. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The business's 50-day moving average price is $23.14 and its 200-day moving average price is $24.93.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the firm earned $0.82 earnings per share. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.20%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.